Merck Says Verquvo Granted Marketing Authorization in European Union
21 Juli 2021 - 2:15PM
Dow Jones News
By Michael Dabaie
Merck & Co. Inc. said the European Commission granted
marketing authorization for Verquvo to Bayer AG.
In the EU, Verquvo is indicated for the treatment of symptomatic
chronic heart failure. Verquvo is being jointly developed by Merck
and Bayer. Merck has the commercial rights in the U.S. and Bayer
has the exclusive commercial rights in the rest of world.
The U.S. Food and Drug Administration in January approved
Verquvo to reduce the risk of cardiovascular death and heart
failure hospitalization.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 21, 2021 08:10 ET (12:10 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Bayer (TG:BAYN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024